Docetaxel: time to reassess combination strategies
Mené sur 994 patients atteints d'un cancer de la prostate résistant à la castration avec métastases osseuses, cet essai de phase III évalue, du point de vue de la survie sans progression et de la survie globale, l'ajout d'atrasentan, un antagoniste du récepteur de l'endothéline, à un traitement par docétaxel
The treatment of metastatic cancer is a challenge and David Quinn and colleagues present yet another negative result for a drug combination including the taxane docetaxel. Taxanes disrupt microtubule function, thus inhibiting the process of cell division, and are also thought to have radiosensitising effects. In their randomised trial with 996 patients, the investigators showed that the addition of atrasentan, a selective endothelin receptor A antagonist, to standard docetaxel treatment for meta ...
The Lancet Oncology , commentaire, 2012